IDEAYA Biosciences 경영진
경영진 기준 점검 3/4
IDEAYA Biosciences CEO는 Yujiro Hata, Jun2015 에 임명되었습니다 의 임기는 11.25 년입니다. 총 연간 보상은 $9.51M, 7.4% 급여 및 92.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $26.53M 가치에 해당하는 회사 주식의 0.72% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.7 년과 7.9 년입니다.
핵심 정보
Yujiro Hata
최고경영자
US$9.5m
총 보수
| CEO 급여 비율 | 7.36% |
| CEO 재임 기간 | 11.3yrs |
| CEO 지분 보유율 | 0.7% |
| 경영진 평균 재임 기간 | 2.7yrs |
| 이사회 평균 재임 기간 | 7.9yrs |
최근 경영진 업데이트
Recent updates
새로운 내러티브 • Sep 21
Late-Stage Oncology Pipeline And First Product Launch Will Transform Long-Term Earnings Profile
Key Takeaways According to some analysts, IDEAYA Biosciences could potentially turn its late stage darovasertib franchise and growing precision oncology pipeline into a broader oncology platform with multiple potential registrational programs across uveal melanoma, small cell lung cancer and MTAP-deleted tumors. A key focus for the company is successful execution on upcoming clinical and regulatory milestones for darovasertib and IDE849, while advancing PRMT5, MAT2A and KRAS combinations in MTAP-deleted pancreatic and lung cancers within the current cash runway.분석 기사 • Jun 17
IDEAYA Biosciences (IDYA) Stock Could Be 81.5% Below Fair Value After Trial Milestone
IDEAYA Biosciences (IDYA) stock is in focus after the company enrolled the first patient in a Phase 1 trial that combines IDE892 and IDE397 for MTAP-deleted solid tumors, including pancreatic and non-small cell lung cancers. See our latest analysis for IDEAYA Biosciences. At a share price of $30.57, IDEAYA Biosciences has seen strong short term momentum, with a 7 day share price return of 10.76% and a 30 day share price return of 7.94%. However, the 90 day share price return declined 6.23%,...Seeking Alpha • Jun 11
Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026
Summary IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal melanoma and robust clinical progress. The company's darovasertib + crizotinib met the mPFS primary endpoint in 1st-line HLA*A2-negative mUM, supporting an RTOR NDA Accelerated Approval submission filing. Upcoming catalysts include NDA filing submission completion of darovasertib in H2 2026, label expansion data for HLA*A2-positive mUM, and further neoadjuvant/adjuvant melanoma updates. The company boasts a cash runway into 2030, recently raised $300M, and retains U.S. rights plus milestone/royalty upside through its Servier partnership. Read the full article on Seeking Alpha분석 기사 • Jun 02
News Flash: Analysts Just Made A Substantial Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Forecasts
IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • May 08
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates
IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders are probably feeling a little disappointed, since its shares fell...분석 기사 • May 07
Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates
Market forces rained on the parade of IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders today, when the analysts...분석 기사 • Jul 28
We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Apr 16
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later
Summary IDEAYA Biosciences' valuation has declined over 50% since mid-2024, prompting a re-evaluation of its investment potential. The most advanced program, darovasertib, targets tumors with GNAQ/GNA11 mutations, showing promising clinical activity. With over $1 billion in cash and other investments, IDYA has 4–5 years of operational liquidity. Strength: Strong liquidity. Risk: Heavy reliance on key data catalysts for future success. Read the full article on Seeking Alpha분석 기사 • Apr 13
Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Feb 10
Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
Summary Ideaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uveal melanoma; mPFS data expected end of 2025. Darovasertib is also being evaluated in another phase 2 study as a monotherapy targeting neoadjuvant uveal melanoma patients, with data expected in 2025. The global uveal melanoma treatment market is projected to reach $3.22 billion by the end of 2034. IDYA is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028, reducing near-term dilution risk. Read the full article on Seeking Alpha분석 기사 • Jan 03
We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Dec 04
Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
Summary Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead candidate, Darovasertib, shows promising efficacy in metastatic uveal melanoma, especially in combination with crizotinib, addressing a significant unmet medical need. IDE397, another key asset, demonstrated positive interim data in MTAP-deletion cancers, showing a 39% ORR and a strong safety profile. With a market cap of $2.37bn and a cash runway into 2028, IDYA is financially well-positioned, despite the inherent risks of late-stage studies. Read the full article on Seeking AlphaSeeking Alpha • Sep 20
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
Summary IDEAYA Biosciences uses synthetic lethality to target genetic vulnerabilities in cancer cells, focusing on MTAP-deleted tumors. IDE397 demonstrated promising Phase 2 results with high response rates in MTAP-deleted solid tumors. Strategic partnerships with Pfizer, Amgen, Gilead, and GSK validate IDEAYA's technology and offer substantial potential milestone payments. IDE397 shows a 94% disease control rate in Phase 2 trials for MTAP-deleted tumors, with favorable safety and efficacy profiles, positioning it as a potential first-in-class treatment. IDYA has a robust cash runway and reasonable valuation, which is why I rate it a "buy" for long-term biotech investors. Read the full article on Seeking AlphaSeeking Alpha • Jul 08
Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
Summary Ideaya Biosciences is a cancer-focused biotech with promising pipeline candidates darovasertib and IDE397 targeting uveal melanoma and MTAP-deleted cancers. Darovasertib has shown strong results in phase 2 trials for uveal melanoma, while IDE397 demonstrated positive phase 2 data for MTAP-deleted NSCLC and urothelial cancer. With a solid financial position and potential for accelerated approvals, IDYA presents a compelling investment opportunity, although the current valuation may be high. Read the full article on Seeking AlphaSeeking Alpha • Jun 18
Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and has a fortress balance sheet. An updated analysis around Ideaya Biosciences follows in the paragraphs below. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$175m |
| Mar 31 2026 | n/a | n/a | -US$140m |
| Dec 31 2025 | US$10m | US$700k | -US$114m |
| Sep 30 2025 | n/a | n/a | -US$161m |
| Jun 30 2025 | n/a | n/a | -US$332m |
| Mar 31 2025 | n/a | n/a | -US$307m |
| Dec 31 2024 | US$17m | US$646k | -US$274m |
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$154m |
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$6m | US$598k | -US$113m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$68m |
| Dec 31 2022 | US$3m | US$570k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$55m |
| Dec 31 2021 | US$4m | US$544k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$30m |
| Mar 31 2021 | n/a | n/a | -US$31m |
| Dec 31 2020 | US$2m | US$510k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$44m |
| Dec 31 2019 | US$2m | US$457k | -US$42m |
보상 대 시장: Yujiro의 총 보수(USD9.51M)는 US 시장에서 비슷한 규모 기업의 평균(USD7.02M)보다 높습니다.
보상과 수익: Yujiro의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Yujiro Hata (52 yo)
11.3yrs
재임 기간
US$9,512,640
보수
Mr. Yujiro S. Hata is Director since November 2024 at Hexagon Bio, Inc. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences,...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 11.3yrs | US$9.51m | 0.72% $ 26.5m | |
| Chief Financial Officer | 1.3yrs | US$4.15m | 0% $ 0 | |
| Chief Accounting Officer | 3.2yrs | US$1.65m | 0.027% $ 1.0m | |
| Chief Scientific Officer | 4.9yrs | US$3.32m | 0% $ 0 | |
| Chief Legal Officer | 2yrs | US$1.13m | 0.0022% $ 80.1k | |
| Chief Medical Officer | 3.8yrs | US$3.33m | 0% $ 0 | |
| Chief Technology Officer | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Head of Human Resources | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Medical Writing & Project Management | 4.5yrs | 데이터 없음 | 데이터 없음 | |
| Chief Business Officer | 2.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | 1.8yrs | US$3.42m | 데이터 없음 | |
| Senior Vice President of Late Phase Clinical Development & Strategy | 1.7yrs | 데이터 없음 | 데이터 없음 |
2.7yrs
평균 재임 기간
52yo
평균 나이
경험이 풍부한 관리: IDYA의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.7 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 11.3yrs | US$9.51m | 0.72% $ 26.5m | |
| Independent Director | 6.8yrs | US$344.16k | 0% $ 0 | |
| Independent Director | 10.9yrs | US$351.66k | 0.056% $ 2.1m | |
| Chair of Scientific Advisory Board | 7.6yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 8.2yrs | US$351.66k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$334.16k | 0% $ 0 | |
| Member of Scientific Advisory Board | 10.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 7.6yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 10.3yrs | 데이터 없음 | 데이터 없음 | |
| Lead Independent Director | 10.7yrs | US$379.16k | 0.0085% $ 313.9k | |
| Independent Director | 6.3yrs | US$331.66k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.8yrs | 데이터 없음 | 데이터 없음 |
7.9yrs
평균 재임 기간
68yo
평균 나이
경험이 풍부한 이사회: IDYA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.9 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/21 08:46 |
| 종가 | 2026/09/21 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
IDEAYA Biosciences, Inc.는 28명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Madhu Kumar | Baird |
| Zhiqiang Shu | Berenberg |
| Li Wang Watsek | Cantor Fitzgerald & Co. |